Synthesis and biological activities of the respiratory chain inhibitor aurachin D and new ring versus chain analogues

Scholarly Works

• Saha, P.; Das, S.; Indurthi, H. K.; Kumar, R.; Roy, A.; Kalia, N. P.; Sharma, D. K. Cytochrome bd oxidase: an emerging anti-tubercular drug target. RSC medicinal chemistry 2024, 15, 769–787. doi:10.1039/d3md00587a
• Kruth, S.; Nett, M. Aurachins, Bacterial Antibiotics Interfering with Electron Transport Processes. Antibiotics (Basel, Switzerland) 2023, 12, 1067. doi:10.3390/antibiotics12061067
• Kruth, S.; Zimmermann, C. J.-M.; Kuhr, K.; Hiller, W.; Lütz, S.; Pietruszka, J.; Kaiser, M.; Nett, M. Generation of Aurachin Derivatives by Whole-Cell Biotransformation and Evaluation of Their Antiprotozoal Properties. Molecules (Basel, Switzerland) 2023, 28, 1066. doi:10.3390/molecules28031066
• Jeffreys, L. N.; Ardrey, A.; Hafiz, T. A.; Dyer, L.-A.; Warman, A. J.; Mosallam, N.; Nixon, G. L.; Fisher, N. E.; Hong, W. D.; Leung, S. C.; Aljayyoussi, G.; Bibby, J.; Almeida, D. V.; Converse, P. J.; Fotouhi, N.; Berry, N. G.; Nuermberger, E. L.; Upton, A. M.; O'Neill, P. M.; Ward, S. A.; Biagini, G. A. Identification of 2-Aryl-Quinolone Inhibitors of Cytochrome bd and Chemical Validation of Combination Strategies for Respiratory Inhibitors against Mycobacterium tuberculosis. ACS infectious diseases 2023, 9, 221–238. doi:10.1021/acsinfecdis.2c00283
• Zhou, Y.; Shao, M.; Wang, W.; Cheung, C.-Y.; Wu, Y.; Yu, H.; Hu, X.; Cook, G. M.; Gong, H.; Lu, X. Discovery of 1-hydroxy-2-methylquinolin-4(1H)-one derivatives as new cytochrome bd oxidase inhibitors for tuberculosis therapy. European journal of medicinal chemistry 2022, 245, 114896. doi:10.1016/j.ejmech.2022.114896
• Kruth, S.; Schibajew, L.; Nett, M. Biocatalytic production of the antibiotic aurachin D in Escherichia coli. AMB Express 2022, 12, 138. doi:10.1186/s13568-022-01478-8
• Lawer, A.; Tyler, C.; Hards, K.; Keighley, L. M.; Cheung, C.-Y.; Kierek, F.; Su, S.; Matikonda, S. S.; McInnes, T.; Tyndall, J. D. A.; Krause, K. L.; Cook, G. M.; Gamble, A. B. Synthesis and Biological Evaluation of Aurachin D Analogues as Inhibitors of Mycobacterium tuberculosis Cytochrome bd Oxidase. ACS medicinal chemistry letters 2022, 13, 1663–1669. doi:10.1021/acsmedchemlett.2c00401
• Bader, C. D.; Panter, F.; Garcia, R.; Tchesnokov, E. P.; Haid, S.; Walt, C.; Spröer, C.; Kiefer, A. F.; Götte, M.; Overmann, J.; Pietschmann, T.; Müller, R. Sandacrabins - Structurally Unique Antiviral RNA Polymerase Inhibitors from a Rare Myxobacterium. Chemistry (Weinheim an der Bergstrasse, Germany) 2022, 28, e202104484. doi:10.1002/chem.202104484
• Radloff, M.; Elamri, I.; Grund, T. N.; Witte, L. F.; Hohmann, K. F.; Nakagaki, S.; Goojani, H. G.; Nasiri, H.; Hideto Miyoshi; Bald, D.; Xie, H.; Sakamoto, J.; Schwalbe, H.; Safarian, S. Short-chain aurachin D derivatives are selective inhibitors of E. coli cytochrome bd-I and bd-II oxidases. Scientific reports 2021, 11, 23852. doi:10.1038/s41598-021-03288-7
• Speicher, A.; Stief, L. Setup of 4-Prenylated Quinolines through Suzuki-Miyaura Coupling for the Synthesis of Aurachins A and B. Advanced Synthesis & Catalysis 2021, 364, 158–164. doi:10.1002/adsc.202100884
• Ronzon, Q.; Zhang, W.; Casaretto, N.; Mouray, E.; Florent, I.; Nay, B. Programmed Multiple C-H Bond Functionalization of the Privileged 4-hydroxyquinoline Template. Chemistry (Weinheim an der Bergstrasse, Germany) 2021, 27, 7764–7772. doi:10.1002/chem.202100929
• Asseri, A. H.; Godoy-Hernandez, A.; Goojani, H. G.; Lill, H.; Sakamoto, J.; McMillan, D. G. G.; Bald, D. Cardiolipin enhances the enzymatic activity of cytochrome bd and cytochrome bo 3 solubilized in dodecyl-maltoside. Scientific reports 2021, 11, 8006. doi:10.1038/s41598-021-87354-0
• Wicker, G.; Schoch, R.; Paradies, J. Diastereoselective Synthesis of Dihydro-quinolin-4-ones by a Borane-Catalyzed Redox-Neutral endo-1,7-Hydride Shift. Organic letters 2021, 23, 3626–3630. doi:10.1021/acs.orglett.1c01018
• Hasenoehrl, E. J.; Wiggins, T. J.; Berney, M. Bioenergetic Inhibitors: Antibiotic Efficacy and Mechanisms of Action in Mycobacterium tuberculosis. Frontiers in cellular and infection microbiology 2021, 10, 611683. doi:10.3389/fcimb.2020.611683
• Malík, I.; Čižmárik, J.; Kováč, G.; Pecháčová, M.; Hudecova, L. Telacebec (Q203): Is there a novel effective and safe anti-tuberculosis drug on the horizon?. Ceska a Slovenska farmacie : casopis Ceske farmaceuticke spolecnosti a Slovenske farmaceuticke spolecnosti 2021, 70, 164–171. doi:10.5817/csf2021-5-164
• doi:10.1002/9783527828166.ch10
• Lee, B. S.; Hards, K.; Engelhart, C. A.; Hasenoehrl, E. J.; Kalia, N. P.; Mackenzie, J. S.; Sviriaeva, E. N.; Chong, S. S. M.; Manimekalai, M. S. S.; Koh, V. H. Q.; Chan, J.; Xu, J.; Alonso, S.; Miller, M. J.; Steyn, A. J. C.; Grüber, G.; Schnappinger, D.; Berney, M.; Cook, G. M.; Moraski, G. C.; Pethe, K. Dual inhibition of the terminal oxidases eradicates antibiotic-tolerant Mycobacterium tuberculosis. EMBO molecular medicine 2020, 13, e13207. doi:10.15252/emmm.202013207
• Bajeli, S.; Baid, N.; Kaur, M.; Pawar, G. P.; Chaudhari, V. D.; Kumar, A. Terminal Respiratory Oxidases: A Targetables Vulnerability of Mycobacterial Bioenergetics?. Frontiers in cellular and infection microbiology 2020, 10, 589318. doi:10.3389/fcimb.2020.589318
• Appetecchia, F.; Consalvi, S.; Scarpecci, C.; Biava, M.; Poce, G. SAR Analysis of Small Molecules Interfering with Energy-Metabolism in Mycobacterium tuberculosis. Pharmaceuticals (Basel, Switzerland) 2020, 13, 227. doi:10.3390/ph13090227
• Sester, A.; Stüer-Patowsky, K.; Hiller, W.; Kloss, F.; Lütz, S.; Nett, M. Biosynthetic Plasticity Enables Production of Fluorinated Aurachins. Chembiochem : a European journal of chemical biology 2020, 21, 2268–2273. doi:10.1002/cbic.202000166

Explore citations to this article at